Skip to content

A clinical trial to evaluate the safety and efficacy of recombinant collagen dressings for postoperative wound repair after photoelectric therapy

A clinical trial to evaluate the safety and efficacy of recombinant collagen dressings for postoperative wound repair after photoelectric therapy

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200058855
Enrollment
Unknown
Registered
2022-04-18
Start date
2022-05-04
Completion date
Unknown
Last updated
2024-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Skin wound after photoelectric technology treatment

Interventions

Test group:Recombinant Collagen Dressing
Control group:Collagen Dressing (animal collagen)

Sponsors

Shanghai Tong Ren Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. 18 to 60 years old (inclusive), gender is not limited; 2. Facial laser surgery or photon surgery is planned, and the skin barrier in the surgical area is damaged (the postoperative wound surface should not exceed the dermis layer, and the scanning area of a single spot should not exceed 20mm*20mm); 3. Voluntarily participate in this clinical trial and have signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. Known history of allergy to the components of the test product (collagen); 2. People with light sensitivity, and taking light sensitive drugs within the past 1 month; 3. Skin cancer or skin ulceration and inflammation; 4. A history of diabetes and vascular disease; 5. Allergic constitution or previous severe allergic reaction (such as anaphylactic shock); 6. Scar constitution; 7. The skin has been exposed to the sun within the past 1 month; 8. Currently receiving radiotherapy and chemotherapy or taking hormone or immunosuppressive therapy; 9. Severe cardiac, hepatic and renal dysfunction (heart function: grade III and above; ALT and AST > 3 times the upper limit of normal; serum creatinine > 1.5 times the upper limit of normal); 10. Those who are alcoholics, persons with severe mental disorders or who cannot cooperate with medical treatment; 11. Women who have a family plan within 1 month, or are pregnant and breastfeeding; 12. Participated in any other drug or medical device clinical trials within 3 months before screening; 13. Other circumstances in which the researcher believes that the subjects are not suitable to participate in this trial.

Design outcomes

Primary

MeasureTime frame
Total efficiency;

Secondary

MeasureTime frame
Subject perceived symptom score;Pain score (Visual Analog Score);Subject's perceived comfort;Red areas and brown spots;

Countries

China

Contacts

Public ContactSong Ningjing

Shanghai Tong Ren Hospital

SNJ3367@shtrhospital.com+86 18121226906

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026